David Fox

The U.S. Food and Drug Administration (FDA) has finalized guidance on clinical investigations for psychedelic drugs, clarifying trial issues including study design, data collection, and patient monitoring. Against the...more On April 22, 2026, the Acting U.S. Attorney General ordered two categories of marijuana moved from Schedule I to Schedule III of the Controlled Substances Act (CSA): FDA-approved drug products containing marijuana, and...more On December 18, 2025, President Trump signed an Executive Order (the “EO”) directing the Department of Justice (DOJ) to complete the rulemaking process related to rescheduling marijuana to Schedule III and committing to...more On August 15, 2025, the U.S. Court of Appeals for the D.C. Circuit limited FDA's ability to deny a hearing on the approvability of a new drug application (NDA) based on a lack of “substantial evidence.”...more